Eli Lilly is setting the stage for a strong 2025, with its fourth-quarter results and forward guidance reflecting solid momentum. The company's adjusted earnings per share are exp ...

Eli Lilly and Co (NYSE:LLY) stock is trading higher after the company released better-than-expected fourth-quarter earnings ...

Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator ...

Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from Mounjaro and Zepbound. Non-incretin revenue(i) grew by 20% compared to Q4 2023. Pipeline ...

Learn more about whether AbbVie Inc. or Genmab A/S is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Pyoderma gangrenosum and metastatic Crohn's disease can resemble the ulcerative phase of PAN. Other connective tissue diseases such as systemic lupus erythematosus, rheumatoid arthritis ...

Welcome to the AbbVie fourth-quarter 2024 Earnings Conference Call. [Operator instructions] Today's call is also being ...

The trial enrolled patients with moderately to severely active Crohn's disease who had experienced ... locally advanced or metastatic breast cancer who have BRCA1 or BRCA2 mutations and have ...

According to GlobalData, Phase I drugs for Metastatic Colorectal Cancer have an 84% phase ... The company is also developing pipeline products for the treatment of cancer, Crohn’s disease, anemia, ...

A Personal View published in The Lancet Oncology challenges the long-standing perception of metastatic brain cancer, calling ...